# A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia

Study · id `cardio:ct-nct07610278` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07610278](<https://clinicaltrials.gov/study/NCT07610278>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07610278

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT07610278. Randomized; double masking; primary purpose treatment. Start 2026-05-29 (actual); primary completion 2027-04-28 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT07610278, source copy `cardio:ctgov-nct07610278-2026-07-30`, retrieved 2026-10-26)
- Started: 2026-05-29 (actual) (ClinicalTrials.gov record NCT07610278, source copy `cardio:ctgov-nct07610278-2026-07-30`, retrieved 2026-10-26)
- Primary completion: 2027-04-28 (anticipated) (ClinicalTrials.gov record NCT07610278, source copy `cardio:ctgov-nct07610278-2026-07-30`, retrieved 2026-10-26)
- Completion: 2028-02-03 (anticipated) (ClinicalTrials.gov record NCT07610278, source copy `cardio:ctgov-nct07610278-2026-07-30`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT07610278, source copy `cardio:ctgov-nct07610278-2026-07-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07610278-2026-07-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia
- Condition: Hypercholesterolaemia
- Intervention (Drug): QCZ484
- Intervention (Drug): Inclisiran
- Intervention (Drug): QCZ484 placebo
- Intervention (Drug): Inclisiran placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 44d7024367a651581bb12cd00b496251d211218ab0396e799950c59c002c096f
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
